Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)]

Evan Y. Yu; Josep M. Piulats; Gwenaelle Gravis; Peter C.C. Fong; Tilman Todenhöfer; Brigitte Laguerre; Jose A. Arranz; Stephane Oudard; Christophe Massard; Julia Heinzelbecker; Luke T. Nordquist; Joan Carles; Michael P. Kolinsky; Marinela Augustin; Howard Gurney; Ali Tafreshi; Xin Tong Li; Ping Qiu; Christian H. Poehlein; Charles Schloss; Johann S. de Bono

doi:10.1016/j.eururo.2022.11.025

Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)]

Evan Y. Yu, Josep M. Piulats, Gwenaelle Gravis, Peter C.C. Fong, Tilman Todenhöfer, Brigitte Laguerre, Jose A. Arranz, Stephane Oudard, Christophe Massard, Julia Heinzelbecker, Luke T. Nordquist, Joan Carles, Michael P. Kolinsky, Marinela Augustin, Howard Gurney, Ali Tafreshi, Xin Tong Li, Ping Qiu, Christian H. Poehlein, Charles SchlossJohann S. de Bono

Résultats de recherche: Contribution à un journal › !!Comment/debate

Résumé

The authors regret that there was an error in the supplementary files – Table 6. The correct values for ‘Severe skin reaction’ are shown below, and also updated online accordingly. [Table presented]The authors would like to apologise for any inconvenience caused.

langue originale	Anglais
Pages (de - à)	e87
journal	European Urology
Volume	83
Numéro de publication	3
Les DOIs	https://doi.org/10.1016/j.eururo.2022.11.025
état	Publié - 1 mars 2023

Accès au document

10.1016/j.eururo.2022.11.025

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Yu, E. Y., Piulats, J. M., Gravis, G., Fong, P. C. C., Todenhöfer, T., Laguerre, B., Arranz, J. A., Oudard, S., Massard, C., Heinzelbecker, J., Nordquist, L. T., Carles, J., Kolinsky, M. P., Augustin, M., Gurney, H., Tafreshi, A., Li, X. T., Qiu, P., Poehlein, C. H., ... de Bono, J. S. (2023). Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)]. European Urology, 83(3), e87. https://doi.org/10.1016/j.eururo.2022.11.025

Yu, Evan Y. ; Piulats, Josep M. ; Gravis, Gwenaelle et al. / Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer : Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)]. Dans: European Urology. 2023 ; Vol 83, Numéro 3. p. e87.

@article{b9813f0a860b477b9d45acec1f1f275a,

title = "Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)]",

abstract = "The authors regret that there was an error in the supplementary files – Table 6. The correct values for {\textquoteleft}Severe skin reaction{\textquoteright} are shown below, and also updated online accordingly. [Table presented]The authors would like to apologise for any inconvenience caused.",

author = "Yu, {Evan Y.} and Piulats, {Josep M.} and Gwenaelle Gravis and Fong, {Peter C.C.} and Tilman Todenh{\"o}fer and Brigitte Laguerre and Arranz, {Jose A.} and Stephane Oudard and Christophe Massard and Julia Heinzelbecker and Nordquist, {Luke T.} and Joan Carles and Kolinsky, {Michael P.} and Marinela Augustin and Howard Gurney and Ali Tafreshi and Li, {Xin Tong} and Ping Qiu and Poehlein, {Christian H.} and Charles Schloss and {de Bono}, {Johann S.}",

note = "Publisher Copyright: {\textcopyright} 2022",

year = "2023",

month = mar,

day = "1",

doi = "10.1016/j.eururo.2022.11.025",

language = "English",

volume = "83",

pages = "e87",

journal = "European Urology",

issn = "0302-2838",

number = "3",

}

Yu, EY, Piulats, JM, Gravis, G, Fong, PCC, Todenhöfer, T, Laguerre, B, Arranz, JA, Oudard, S, Massard, C, Heinzelbecker, J, Nordquist, LT, Carles, J, Kolinsky, MP, Augustin, M, Gurney, H, Tafreshi, A, Li, XT, Qiu, P, Poehlein, CH, Schloss, C & de Bono, JS 2023, 'Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)]', European Urology, VOL. 83, Numéro 3, p. e87. https://doi.org/10.1016/j.eururo.2022.11.025

Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)]. / Yu, Evan Y.; Piulats, Josep M.; Gravis, Gwenaelle et al.
Dans: European Urology, Vol 83, Numéro 3, 01.03.2023, p. e87.

Résultats de recherche: Contribution à un journal › !!Comment/debate

TY - JOUR

T1 - Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer

T2 - Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)]

AU - Yu, Evan Y.

AU - Piulats, Josep M.

AU - Gravis, Gwenaelle

AU - Fong, Peter C.C.

AU - Todenhöfer, Tilman

AU - Laguerre, Brigitte

AU - Arranz, Jose A.

AU - Oudard, Stephane

AU - Massard, Christophe

AU - Heinzelbecker, Julia

AU - Nordquist, Luke T.

AU - Carles, Joan

AU - Kolinsky, Michael P.

AU - Augustin, Marinela

AU - Gurney, Howard

AU - Tafreshi, Ali

AU - Li, Xin Tong

AU - Qiu, Ping

AU - Poehlein, Christian H.

AU - Schloss, Charles

AU - de Bono, Johann S.

PY - 2023/3/1

Y1 - 2023/3/1

N2 - The authors regret that there was an error in the supplementary files – Table 6. The correct values for ‘Severe skin reaction’ are shown below, and also updated online accordingly. [Table presented]The authors would like to apologise for any inconvenience caused.

AB - The authors regret that there was an error in the supplementary files – Table 6. The correct values for ‘Severe skin reaction’ are shown below, and also updated online accordingly. [Table presented]The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85144754327&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2022.11.025

DO - 10.1016/j.eururo.2022.11.025

M3 - Comment/debate

C2 - 36528479

AN - SCOPUS:85144754327

SN - 0302-2838

VL - 83

SP - e87

JO - European Urology

JF - European Urology

IS - 3

ER -

Yu EY, Piulats JM, Gravis G, Fong PCC, Todenhöfer T, Laguerre B et al. Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)]. European Urology. 2023 mars 1;83(3):e87. doi: 10.1016/j.eururo.2022.11.025